Wells Fargo & Company Akero Therapeutics, Inc. Transaction History

Wells Fargo & Company

$429 Billion
Q1 2025

A detailed history of Wells Fargo & Company transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 43,736 shares of AKRO stock, worth $2.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,736

Previous 61,867 29.31%

Holding current value

$2.03 Million

Previous $1.72 Million 2.85%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$21.87 - $57.56 $396,524 - $1.04 Million	-18,131 Reduced 29.31%	43,736 $1.77 Million
Q4 2024 Feb 12, 2025	BUY	$26.75 - $35.28 $202,952 - $267,669	7,587 Added 13.98%	61,867 $1.72 Million
Q3 2024 Nov 13, 2024	BUY	$21.45 - $29.34 $532,582 - $728,482	24,829 Added 84.31%	54,280 $1.56 Million
Q2 2024 Aug 13, 2024	BUY	$18.31 - $24.62 $170,740 - $229,581	9,325 Added 46.33%	29,451 $690,000
Q1 2024 May 10, 2024	BUY	$17.76 - $31.18 $102,350 - $179,690	5,763 Added 40.12%	20,126 $508,000
Q4 2023 Feb 09, 2024	SELL	$11.38 - $50.33 $355,545 - $1.57 Million	-31,243 Reduced 68.51%	14,363 $335,000
Q3 2023 Nov 13, 2023	SELL	$41.19 - $52.25 $117,185 - $148,651	-2,845 Reduced 5.87%	45,606 $2.31 Million
Q2 2023 Aug 15, 2023	BUY	$36.89 - $56.88 $436,556 - $673,117	11,834 Added 32.32%	48,451 $2.26 Million
Q1 2023 May 12, 2023	BUY	$37.27 - $50.24 $1.3 Million - $1.75 Million	34,800 Added 1915.24%	36,617 $1.4 Million
Q4 2022 Feb 13, 2023	BUY	$33.44 - $54.8 $2,742 - $4,493	82 Added 4.73%	1,817 $99,000
Q3 2022 Nov 14, 2022	SELL	$10.15 - $34.05 $680 - $2,281	-67 Reduced 3.72%	1,735 $59,000
Q2 2022 Aug 12, 2022	SELL	$8.0 - $15.01 $18,288 - $34,312	-2,286 Reduced 55.92%	1,802 $17,000
Q1 2022 May 16, 2022	SELL	$12.97 - $22.26 $114,940 - $197,268	-8,862 Reduced 68.43%	4,088 $58,000
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $247,838 - $327,291	12,473 Added 2614.88%	12,950 $274,000
Q3 2021 Nov 15, 2021	BUY	$18.65 - $25.46 $4,662 - $6,365	250 Added 110.13%	477 $11,000
Q2 2021 Aug 16, 2021	SELL	$24.81 - $32.35 $3,721 - $4,852	-150 Reduced 39.79%	227 $6,000
Q1 2021 May 13, 2021	SELL	$24.04 - $34.19 $712,665 - $1.01 Million	-29,645 Reduced 98.74%	377 $11,000
Q4 2020 Feb 09, 2021	BUY	$25.12 - $29.89 $593,560 - $706,270	23,629 Added 369.61%	30,022 $774,000
Q3 2020 Nov 05, 2020	SELL	$30.79 - $39.92 $460,033 - $596,444	-14,941 Reduced 70.03%	6,393 $196,000
Q2 2020 Aug 13, 2020	BUY	$19.25 - $26.76 $292,388 - $406,457	15,189 Added 247.18%	21,334 $532,000
Q1 2020 May 14, 2020	BUY	$12.8 - $27.05 $78,656 - $166,222	6,145 New	6,145 $130,000

Others Institutions Holding AKRO

# of Institutions

270

Shares Held

86M

Call Options Held

1.02M

Put Options Held

823K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.15B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Akero Therapeutics, Inc. Transaction History